rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Margaret G. McGlynn

Director

Company insider

Files Form 4 as: Director, Novavax; Director, Amicus Therapeutics; Director, Vertex Pharmaceuticals; Director, Air Products and Chemicals; President, MV & ID, Merck & Co.

Every Form 4 they filed

In numbers

Trades disclosed
298
Buys
6
Sells
20
Bought
$151K
Sold
$22.0M
Companies
5
Companies where not an officer
4
First trade
31 Dec 2005
Last trade
20 Jun 2026
Last filed
23 Jun 2026

Companies traded

Where they are an officer
Merck & CoOfficer · last 24 Apr 20090 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
NVAX NovavaxDirector · Biotechnology · last 20 Jun 20260 buys · 0 sells
Amicus TherapeuticsDirector · Biotechnology · last 27 Apr 20261 buy · 8 sells
VRTX Vertex PharmaceuticalsDirector · Biotechnology · last 1 May 20235 buys · 12 sells
APD Air Products and ChemicalsDirector · Chemicals · last 30 Sep 20200 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
20 Jun 2026filed 23 Jun 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—18,880filing
20 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—18,880 at $0.00filing
20 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—18,880 at $0.00filing
20 Jun 2026filed 23 Jun 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—18,880filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—21,270 at $0.00filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—14,180 at $0.00filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—21,270 at $0.00filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—14,180 at $0.00filing
27 Apr 2026filed 27 Apr 2026Amicus TherapeuticsBiotechnologySEC FORM 4 Code D$1.4M94,631 at $14.50filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—74,872filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,000filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—16,236filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—20,000filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—16,236filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—19,473filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—18,574filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—36,111filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—45,423filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—30,474filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—42,467filing

Sectors

Health Care17
Not placed9

Buys in green, sells in red, by the company’s sector.

Related people

David J. TaylorRepresentative, OH-02 · Also traded VRTX in the last 90 days
Donald J. TrumpPresident · Also traded VRTX in the last 90 days